An interventional study of Prednisolone and Methotrexate in Idiopathic Granulomatous Mastitis, sponsored by Kasr El Aini Hospital. Recruiting at 1 site in Egypt. Open to female participants. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Kasr El Aini Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The present study aims to compare the use of systemic steroids, to the combination of systemic steroids and methotrexate and to the combination of systemic steroids with methotrexate and mycophenolate mofetil in the treatment of idiopathic granulomatous mastitis. Also, this study aims to show the response to medical treatment on subsequent US examinations.
23 studies on the registry are indexed under Granulomatous Mastitis; 8 are open to participants now.
This study's planned enrollment of 90 is above the median of 72 across 13 interventional studies indexed under Granulomatous Mastitis.
Browse Granulomatous Mastitis studies →Kasr El Aini Hospital is the lead sponsor of 288 studies on the registry; 35 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
30 female patients with histopathologically confirmed idiopathic granulomatous mastitis
Drug: Prednisolone
30 female patients with histopathologically confirmed idiopathic granulomatous mastitis
Drug: Prednisolone · Drug: Methotrexate
30 female patients with histopathologically confirmed idiopathic granulomatous mastitis
Drug: Prednisolone · Drug: Methotrexate · Drug: Mycofenolate mofetil
Systemic prednisolone at an initial dose of 30 mg/day
Systemic prednisolone (30 mg/day) combined with oral/subcutaneous methotrexate (25 mg/week) plus folic acid supplementation (10 mg/week).
Systemic prednisolone (30 mg/day), methotrexate (25 mg/week with folic acid), and mycophenolate mofetil (1g/day in divided doses)."
Complete Response
Defined as achieving both complete clinical and radiologic remission at 6 months
Time frame: 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methotrexate